EXECUTIVE SUMMARY

ONEighty C Technologies Corporation
70 Blanchard Road, Burlington, MA, USA 01803
http://www.oneightyc.com
eric.walters@oneightyc.com

Founded in 2013
Delaware C Corp, registered in Massachusetts

Mission

Develop market leadership by offering advanced solutions that set new standards for high-performance medical device sterilization and verification

Leadership

Eric G. Walters, Co-Founder & CEO
Michael G. Fritz, Board of Directors
Theresa O'Keefe, Ph.D., Scientific Development
Michael Drues, Ph.D., Regulatory Strategy

Intellectual Property

Three issued US patents. US and foreign patent applications pending

Global Infection Control Crisis

- Current, decades-old reprocessing methods only reach high level disinfection, not sterilization, for temperature-sensitive medical devices such as endoscopes
- Annually, $9.8 billion is spent overall in the U.S. alone due to hospital-acquired infections (HAI)
- Verification of existing reprocessing methods (including autoclaves) is limited to chemical, temperature, and non-pathogen-specific tests
- FDA spotlights: Patient deaths from CRE-infected duodenoscopes and *C. diff.* infections

*WAVE*Pulse™ Sterilization and SterileTest™ Verification

- Successful sterilization tests in lumens and elevator mechanism of a duodenoscope
- Durability tests for endoscopes undergoing ***WAVE*Pulse™ Sterilization** process
- US and foreign patent-pending technology destroys proteins, including prions, thereby making pathogens noninfectious
- Non-toxic sterilization technology is designed to deliver critical time and temperature commercialization parameters
- Simple, rapid, highly-accurate, and patent pending test methods validate virtually every medically-critical bacterial and fungal pathogen

Protein Destruction Delivers Sterilization

- Infectious pathogens require proteins for survival. If proteins are destroyed, pathogens will not cause infection
- Current technologies can't reliably destroy proteins, resulting in many medical devices not being sterilized – especially those with materials that are temperature sensitive



***WAVE*Pulse™ Sterilization** addresses the common problems of equipment cross-contamination and incomplete disinfection that contribute to approximately 100,000 U.S. based HAI-related deaths annually. **SterileTest™ Verification** methods deliver the ability to assure sterilization, disinfection and immunization levels, irrespective of the method used

Target Opportunities

Target markets include healthcare facilities, medical equipment suppliers, instrument manufacturers, and medical device reprocessors that require consistent sterilization and terminal destruction of persistent pathogens, infectious agents, and toxins if enabling technologies were available. Initial target regions include the US and Europe.